Despite revenue growth from pharmacy acquisitions and ZYPITAMAG sales, the significant widening of losses and declining cash position raise concerns about profitability and sustainability. The negative analyst consensus and declining AGGRASTAT sales due to generic competition suggest continued challenges. Monitor the upcoming conference call for guidance on profitability timelines.
Price Chart
Executive Summary
Medicure Inc. reported its 2025 financial results, showing a significant increase in total revenue to $28.9 million from $21.9 million in 2024, driven by pharmacy segment growth. However, the company's net loss widened to $7.1 million from $1.0 million, primarily due to a $2.1 million CMS rebate liability, increased R&D spending, and acquisition-related expenses.
Key Facts
- Total net revenue increased to $28.9 million in 2025 from $21.9 million in 2024
- Net loss widened to $7.1 million ($0.68 per share) from $1.0 million ($0.10 per share) in 2024
- AGGRASTAT revenue declined to $5.7 million from $8.1 million due to generic competition
- Pharmacy segment revenue grew to $20.3 million, including $12.8 million from Marley Drug and $7.5 million from newly acquired Gateway and West Olympia pharmacies
- ZYPITAMAG revenue increased to $6.5 million from $6.2 million
- Adjusted EBITDA was negative $1.5 million compared to negative $437,000 in 2024
- Cash decreased to $3.8 million from $7.2 million due to pharmacy acquisitions
Financial Impact
Revenue increased by $7 million (32% growth) but net loss increased by $6.1 million. The company's cash position decreased by $3.4 million to $3.8 million.
Risk Factors
- Continued decline in AGGRASTAT revenue due to generic competition
- Increased expenses from acquisitions and R&D may continue to pressure profitability
- Low cash balance of $3.8 million limits financial flexibility
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001654954-26-003881 |
| Document: med_6k.htm | 0001654954-26-003881 |
| Document: 0001654954-26-003881-index-headers.html | 0001654954-26-003881 |
| Document: 0001654954-26-003881-index.html | 0001654954-26-003881 |
| Document: 0001654954-26-003881.txt | 0001654954-26-003881 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
May 21, 2026 22w ago | 6-K | $0.8000 $0.9200 | ▲ +15.00% | ▲ +11.81% | $3.16 (+295.00%) |
May 21, 2026 22w ago | 6-K | $0.8000 $0.9200 | ▲ +15.00% | ▲ +11.81% | $3.16 (+295.00%) |
Apr 24, 2026 26w ago | 6-K | $0.7500 $0.8600 | ▼ −14.67% | ▼ −9.59% | $3.16 (−321.33%) |
Apr 22, 2026 26w ago | 6-K | $0.9600 $0.8600 | ▼ −10.42% | ▼ −15.43% | $3.16 (+229.17%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers